These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1924427)

  • 41. Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.
    Ziegler EJ; Douglas H; Sherman JE; Davis CE; Braude AI
    J Immunol; 1973 Aug; 111(2):433-8. PubMed ID: 4577881
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock.
    Jansen PM; Eisele B; de Jong IW; Chang A; Delvos U; Taylor FB; Hack CE
    J Immunol; 1998 Jan; 160(1):475-84. PubMed ID: 9552006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Septomonab (Centoxin) in the treatment of gram-negative septicemia].
    Fomsgaard A
    Ugeskr Laeger; 1993 Apr; 155(14):1066-71. PubMed ID: 8497944
    [No Abstract]   [Full Text] [Related]  

  • 44. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
    Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
    J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endotoxin shock and colibacillosis.
    Larson KA; Bull EH
    J Am Vet Med Assoc; 1970 Dec; 157(11):1568-70. PubMed ID: 4395008
    [No Abstract]   [Full Text] [Related]  

  • 46. Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.
    Mitov IG; Terziiski DG
    Infection; 1991; 19(6):383-90. PubMed ID: 1816107
    [No Abstract]   [Full Text] [Related]  

  • 47. Human monoclonal antibodies in sepsis.
    de Koning J; Westendorp RG
    Neth J Med; 1992 Apr; 40(3-4):215. PubMed ID: 1603215
    [No Abstract]   [Full Text] [Related]  

  • 48. Therapies directed against endotoxin--has the time come?
    Quezado ZM; Hoffman WD
    West J Med; 1993 Apr; 158(4):424-5. PubMed ID: 8317138
    [No Abstract]   [Full Text] [Related]  

  • 49. Antiendotoxin antibodies: a dead end?
    Cross AS
    Ann Intern Med; 1994 Jul; 121(1):58-60. PubMed ID: 8198349
    [No Abstract]   [Full Text] [Related]  

  • 50. The Jennerian approach to gram-negative bacillary bacteremia?
    Sanford JP
    N Engl J Med; 1972 Aug; 287(6):304-5. PubMed ID: 5038959
    [No Abstract]   [Full Text] [Related]  

  • 51. BSAC, third combined British Scandinavian Hellenic Conference, May 1991: immunotherapy of infectious disease.
    Evans TJ; Cohen J
    J Antimicrob Chemother; 1992 May; 29(5):495-8. PubMed ID: 1624389
    [No Abstract]   [Full Text] [Related]  

  • 52. [Plasma exchange in treatment refractory septic shock : Presentation of a therapeutic add-on strategy].
    David S; Hoeper MM; Kielstein JT
    Med Klin Intensivmed Notfmed; 2017 Feb; 112(1):42-46. PubMed ID: 26604091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pathogenesis and potential strategies for prevention and treatment of septic shock: an update.
    Glauser MP; Heumann D; Baumgartner JD; Cohen J
    Clin Infect Dis; 1994 Feb; 18 Suppl 2():S205-16. PubMed ID: 8148464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lactobacillus overgrowth diet as an aid in controlling Escherichia coli septicemia and endotoxemia in cancer patients: a case report.
    Ellis S; Spratt JS
    J Am Geriatr Soc; 1970 May; 18(5):410-5. PubMed ID: 4985582
    [No Abstract]   [Full Text] [Related]  

  • 55. New aspects in the treatment of gram-negative bacteraemia and septic shock.
    Schedel I
    Infection; 1988; 16(1):4-7. PubMed ID: 3283037
    [No Abstract]   [Full Text] [Related]  

  • 56. [Prospects of using controlled-action lactoglobulins in the treatment of acute intestinal infections and dysbacteriosis in infants].
    Soboleva SV
    Pediatriia; 1990; (11):48-51. PubMed ID: 2075046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy for sepsis.
    Ralston DR; St John RC
    Clin Chest Med; 1996 Jun; 17(2):307-17. PubMed ID: 8792068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibodies to tumour necrosis factor in the treatment of severe sepsis: rationale and early clinical experience.
    Cohen J
    Prog Clin Biol Res; 1991; 367():187-96. PubMed ID: 1924427
    [No Abstract]   [Full Text] [Related]  

  • 59. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 60. Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria.
    Roger T; Glauser MP; Calandra T
    J Endotoxin Res; 2001; 7(6):456-60. PubMed ID: 11753217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.